MAT Waiver Eligibility Training

*(Live Session)*

*Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.*
The Half and Half Course Agenda

- Overview: Opioid Use Disorder Treatment with Buprenorphine/Naloxone
- Patient Evaluation
- Specialty Topics
- Case Study
- Medication Assisted Treatment Clinical Application
- Case Study
- Urine Drug Testing
- Case Study
- Overview of Clinical Tools
- Completing the Notification of Intent Waiver Form
Speaker Intro
Overview:
Opioid Use Disorder Treatment with Buprenorphine/Naloxone
Target Audience

The overarching goal of PCSS is to train a diverse range of healthcare professionals in the safe and effective prescribing of opioid medications for the treatment of pain, as well as the treatment of substance use disorders, particularly opioid use disorders, with medication-assisted treatments.
History of Opioids

• Utilized throughout the world for various uses for thousands of years

• 1800’s:
  • Morphine and Heroin were marketed commercially as medications for pain, anxiety, respiratory problems
  • Invention of Hypodermic syringe allowed for rapid delivery to the brain
# Pivotal Milestones in Treatment

<table>
<thead>
<tr>
<th>Year</th>
<th>Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td>1970</td>
<td>Methadone is approved by the FDA for <em>detoxification</em></td>
</tr>
<tr>
<td>1973</td>
<td>Methadone is approved by the FDA for <em>maintenance</em></td>
</tr>
<tr>
<td>1974</td>
<td>Opioid Treatment Programs (OTP’s) able to dispense Methadone for maintenance treatment</td>
</tr>
<tr>
<td>1984</td>
<td>Oral Naltrexone is approved by the FDA</td>
</tr>
<tr>
<td>2000</td>
<td>Drug Addiction Treatment Act of 2000 (DATA 2000) allowed qualified physicians to offer Office Based Opioid Treatment (OBOT)</td>
</tr>
<tr>
<td>2002</td>
<td>Buprenorphine is approved by the FDA</td>
</tr>
<tr>
<td>2010</td>
<td>Extended-release injectable naltrexone is approved by the FDA</td>
</tr>
</tbody>
</table>
| 2016 | Comprehensive Addiction and Recovery Act (CARA)  
- Allows Nurse Practitioners and Physician Assistants to become eligible to prescribe buprenorphine for treatment of opioid use disorder |
DATA 2000 – Practitioners
Requirements

- Licensed provider with DEA Registration
- Subspecialty training in addictions or completion of an 8-hour course
- Registration with SAMHSA and DEA
- Must affirm the capacity to refer patients for appropriate counseling and ancillary services
- Must adhere to patient panel size limits
  - 30 during the first year
  - Eligible to apply for increase to 100 after the first year
  - May apply to increase to 275 after being at 100 for a year and meeting specific criteria.
Drug Addiction Treatment Act (DATA 2000)

Permitted physicians who met certain qualifications to treat opioid addiction with:

- Schedule III, IV, and V narcotic medications that had been specifically approved by the FDA or combination of such drugs for the treatment of opioid dependence
- In treatment settings other than the traditional Opioid Treatment Program ("methadone clinic") settings
The Drug Enforcement Administration (DEA) is responsible for ensuring that physicians who are registered with DEA pursuant to the DATA 2000 are in compliance with the Controlled Substance Act.

The primary purpose of the inspection is to ensure compliance with the recordkeeping and appropriate prescribing of controlled substances under CSA and DATA 2000.

You must keep a log of patients who are treated with buprenorphine, if you have this information easily accessible, the inspection should be fairly rapid and non-onerous.

TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Chapter 6, pp 79-85;
Treatment Goals

• Range of treatment goals

Minimization of harms from ongoing use  
Sustained recovery with abstinence from all substances

• Treatment Options; Federations of State Medical Boards 2013
  - Partial Agonist (Buprenorphine) at the mu-receptor – OBOT/OTP
  - Agonist (Methadone) at the mu-receptor - OTP
  - Antagonists (Naltrexone) at the mu-receptor
  - Simple detoxification and no other treatment
  - Counseling and/or peer support without MAT
  - Referral to short or long term residential treatment
• Buprenorphine promotes retention, and those who remain in treatment become more likely over time to abstain from other opioids

Kakko et al, 2003
Soeffing et al., 2009
Benefits of MAT: Decreased Mortality

Death rates:

- General population
- Medication-assisted treatment

Standardized Mortality Ratio

Dupouy et al., 2017
Evans et al., 2015
Sordo et al., 2017
Summary

- A number of legislative initiatives have been passed to improve access to treatment for opioid use disorders.
- DATA 2000 allows for the treatment of opioid use disorder to be treated outside of an Opioid Treatment Program with schedule III, IV, or V medications approved by the FDA.
- MAT for opioid use disorder has several benefits including:
  - Decrease in the number of fatal overdoses
  - Increase patients’ retention in treatment, and improved social functioning
References

References


Pharmacology
Major Features of Methadone

**Full Agonist at mu receptor**

**Long acting**
- Half-life ~ 15-60 Hours

**Weak affinity** for mu receptor
- Can be displaced by partial agonists (e.g. buprenorphine) and antagonists (e.g. naloxone, naltrexone), which can both precipitate withdrawal

**Monitoring**
- Significant respiratory suppression and potential respiratory arrest in overdose
- QT prolongation

---

CSAT, 2005
### Major Features of Buprenorphine

**Partial agonist** at mu receptor
- Comparatively minimal respiratory suppression and no respiratory arrest when used as prescribed

**Long acting**
- Half-life ~ 24-36 Hours

**High affinity** for mu receptor
- Blocks other opioids
- Displaces other opioids
  - Can precipitate withdrawal

**Slow dissociation** from mu receptor
- Stays on receptor for a long time

---

**SAMHSA, 2018**
**Orman & Keating, 2009**
Major Features of Naltrexone

**Full Antagonist** at mu receptor
- Competitive binding at mu receptor

**Long acting**
- Half-life:
  - Oral ~ 4 Hours
  - IM ~ 5-10 days

**High affinity** for mu receptor
- Blocks other opioids
- Displaces other opioids
  - Can precipitate withdrawal

**Formulations**
- Tablets: Revia®: FDA approved in 1984
- Extended-Release intramuscular injection: Vivitrol®: FDA approved in 2010

---

SAMHSA, 2018
Buprenorphine

- Semi-synthetic analogue of thebaine
- Approved by the FDA in 2002 as a Schedule III medication for the treatment of opioid use disorder
- Metabolized in the liver, mainly by cytochrome P450 3A4 (CYP3A4), and has a less-active metabolite, norbuprenorphine
- Most buprenorphine is ultimately excreted into the biliary tract, but small fractions enter the urine and are detectable in urine drug tests
- Because of extensive first-pass metabolism, buprenorphine has poor oral bioavailability when swallowed (<5%), and all therapeutic formulations use other routes
- Sublingual administration bypasses first-pass metabolism and allows bioavailability around 30%

Mendelson et al., 1997
SAMHSA, 2016, 2016
SAMHSA, 2018
How Does Buprenorphine Work?

• AFFINITY is the strength with which a drug physically binds to a receptor
  - Buprenorphine has strong affinity; will displace full mu receptor agonists like heroin and methadone
  - Receptor binding strength, is NOT the same as receptor activation

• DISSOCIATION is the speed (slow or fast) of disengagement or uncoupling of a drug from the receptor
  - Buprenorphine dissociates slowly
  - Buprenorphine stays on the receptor a long time and blocks heroin, methadone and other opioids from binding to those receptors

NOTE: It is unlikely to block all effects from an opioid taken after initiation of buprenorphine treatment. Because binding to mu receptors is a dynamic process; while effects may be less, they are not likely to be completely eliminated.
Buprenorphine Dosing: Efficacy

Ling et al., 1998

% With 13 Consecutive Opiate Free Urines

Buprenorphine dose (mg)

1 4 8 16

Providers Clinical Support System
Mean Heroin Craving: 16 Week Completers: Reduced Craving with Therapeutic Buprenorphine Doses

Ling et al., 1998
Buprenorphine: Maintenance vs. Taper

Fiellin et al., 2014
Common Adverse Effects of Buprenorphine

- Headaches
  - Management: aspirin, ibuprofen, acetaminophen (if there are no contra-indications)

- Nausea
  - Management: Consider spitting the saliva out after adequate absorption instead of swallowing.

- Constipation
  - Management: Stay well-hydrated, Consume high-fiber diet, Consider stool softeners, laxatives, naloxegol

- Xerostomia (Dry mouth) – side effect of ALL opioids
  - Complications: Gingivitis, Periodontitis
  - Management: Stay well-hydrated, Maintain good oral hygiene

SAMHSA, 2018
Wald, 2016
Cognitive and psychomotor effects appear to be negligible.
Respiratory rate slowed but has as a plateau effect in adults.

Nearly all fatal poisonings involve multiple substances.

Hakkinen et al., 2012
Walsh et al., 1994
Rationale for the Combination of Buprenorphine with Naloxone

- When used as prescribed (sublingual or buccal administration), there is minimal bioavailability of naloxone

- Compared to buprenorphine alone, the buprenorphine/naloxone combination:
  - was developed to decrease IV misuse
  - is more likely to precipitate a withdrawal effect if injected by a current opioid user.
  - produces a slowed onset effect when injected or insufflated in those who are physically dependent buprenorphine.
  - per prescription, is less likely to be diverted

Comer et al., 2010
Jones et al., 2015
Stoller et al., 2001
PEAK EFFECTS – MEAN (±SD)
Mendelson J., et.al. Biol Psychiatry 1997;41:1095-1101

Bad Drug

<table>
<thead>
<tr>
<th></th>
<th>Bad Drug Effect (0-100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Buprenorphine placebo, Naloxone placebo</td>
</tr>
<tr>
<td>B</td>
<td>Buprenorphine 0.2 mg, Naloxone placebo</td>
</tr>
<tr>
<td>C</td>
<td>Buprenorphine 0.2 mg, Naloxone 0.1 mg</td>
</tr>
<tr>
<td>D</td>
<td>Buprenorphine placebo, Naloxone 0.1 mg</td>
</tr>
</tbody>
</table>

Sickness

<table>
<thead>
<tr>
<th></th>
<th>Sickness Scale (0-100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Buprenorphine placebo, Naloxone placebo</td>
</tr>
<tr>
<td>B</td>
<td>Buprenorphine 0.2 mg, Naloxone placebo</td>
</tr>
<tr>
<td>C</td>
<td>Buprenorphine 0.2 mg, Naloxone 0.1 mg</td>
</tr>
<tr>
<td>D</td>
<td>Buprenorphine placebo, Naloxone 0.1 mg</td>
</tr>
</tbody>
</table>
Effect of IDU diversion of Buprenorphine and buprenorphine/naloxone combination

Mendelson J., et.al. Biol Psychiatry 1997;41:1095-11
Buprenorphine vs Placebo vs Methadone maintenance for opioid dependence

- Cochrane Review of 31 trials with over 5,400 participants found:
  - Buprenorphine is an effective medication for retaining people in treatment at any dose above 2 mg, and suppressing illicit opioid use (at doses 16 mg or greater) based on placebo-controlled trials.
  - Buprenorphine appears to be less effective than methadone in retaining people in treatment, if prescribed in a flexible dose regimen or at a fixed and low dose (2 - 6 mg per day).
  - However, Buprenorphine prescribed at fixed doses (above 7 mg per day) was not different from methadone prescribed at fixed doses (40 mg or more per day) in retaining people in treatment or in suppression of illicit opioid use.

Mattick et al., 2014
Buprenorphine and Benzodiazepines

- Benzodiazepines are present in most fatal poisonings involving buprenorphine

<table>
<thead>
<tr>
<th>Human studies</th>
<th>Minimal effects on respiration when both are taken at therapeutic doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animal studies</td>
<td>May remove the protective “ceiling effect” and allow buprenorphine to produce fatal respiratory suppression in overdose</td>
</tr>
</tbody>
</table>

- Used as prescribed benzodiazepines in combination with buprenorphine have been associated with more accidental injuries, but not with other safety or treatment outcomes

Bardy et al., 2015
Jones et al., 2012
Nielsen & Taylor, 2005
Schuman-Olivier et al., 2013
# Changes in FDA Recommendations

<table>
<thead>
<tr>
<th>Date</th>
<th>08/2016</th>
<th>09/2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Boxed Warning for combined use of opioid medicines with benzodiazepines or other CNS Depressants (e.g. Alcohol)</td>
<td>Buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS).</td>
</tr>
<tr>
<td></td>
<td>Risks of slowed or difficult breathing; Sedation; Death</td>
<td>The combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Careful medication management by health care professionals can reduce these risks.</td>
</tr>
</tbody>
</table>
FDA Guidance for Health Care Professionals

- Take several actions and precautions and develop a treatment plan when buprenorphine or methadone is used in combination with benzodiazepines or other CNS depressants:
  - Educate patients about the serious risks; poss. death
  - Taper the benzodiazepine or CNS depressant to discontinuation if possible.
  - Verify the diagnosis for anxiety or insomnia and consider other treatment
  - Recognize that patients may require MAT medications indefinitely and their use should continue for as long as patients are benefiting and their use contributes to the intended treatment goals.
  - Coordinate care to ensure other prescribers are aware of the patient’s buprenorphine or methadone treatment.
  - Monitor for illicit drug use, including urine or blood screening
Buprenorphine and Alcohol

- Overall recommendation is to generally avoid CNS depressants with buprenorphine.
- Some evidence that treatment with buprenorphine can help decrease craving for alcohol, ethanol intake and the Addiction Severity Index (ASI) subscale of alcohol use score.
- Alcohol use disorder is associated with higher rates of relapse to opioid use.

Clark et al., 2015
Hakkinen et al., 2012
Nava et al., 2008
Diversion of Buprenorphine

- Has intravenous misuse potential
- Most estimates suggest that, per dose, tablets are more likely to be diverted than films, and mono product tablets more likely than combined buprenorphine/naloxone
- In a survey of more than 4,000 patients in treatment programs in the United States, relative rates of diversion per prescribed dose were:
  - buprenorphine/naloxone film: 1 (reference)
  - buprenorphine/naloxone tablet: 2.2
  - buprenorphine tablet: 6.5
- Combination product is therefore the standard of care for general use

Comer et al., 2010
Jones et al., 2015
Larancea et al., 2014
Lavonas et al., 2014
Naltrexone Treatment

- Naltrexone is a long-acting, high affinity, competitive opioid receptor antagonist with an active metabolite (6-β-naltrexol) which is also an antagonist.
- In sufficient plasma concentrations (>2 ng/ml) naltrexone fully blocks all opioid effects.
- Naltrexone tablet is approved for the treatment of OUD; associated with poor daily adherence.
- Naltrexone (extended release) monthly injection is approved for the treatment of OUD; better compliance.
- Appealing choice for patients who prefer not to be on any opioids.
There may also be a higher proportion of opioid, cocaine, benzodiazepine, cannabinoids, amphetamine - free patients. Comer et al., 2011
Naltrexone Treatment: Mechanism

There are two possible mechanisms of therapeutic effect:

- **Behavioral mechanism**: blockade of the reinforcing effects of heroin leads to gradual extinction of drug seeking and craving
  - Patients who use opioids while on naltrexone experience no effect of exogenous opioids and often stop using them

- **Pharmacological mechanism**: naltrexone decreases reactivity to drug-conditioned cues and decreases craving thereby minimizing pathological responses contributing to relapse

As naltrexone has a different mechanism of action than methadone or buprenorphine, it may be acceptable to, or effective for different subgroups of patients, thus helping to attract more patients into effective treatment overall.
Effectiveness of Buprenorphine vs. Injection Naltrexone

- Two randomized comparative effectiveness trials in Norway and US

- Overall Findings:
  - Once initiated, both medications appear comparably effective, although buprenorphine doses may not have been maximized in the trials
  - Naltrexone is more difficult to initiate due to the need to get a patient through medically supervised withdrawal

Lee et al., 2018
Tanum et al., 2017
Naltrexone Considerations: Initiation

- Official prescribing information recommends that patients be opioid-free followed by a wait-period of 7-10 days before treatment can be initiated, to avoid precipitated withdrawal
  - Can be challenging due to need to tolerate withdrawal symptoms, and remain abstinent over 7 to 10 days
  - Non opioid medications for withdrawal (e.g. clonidine) can be helpful
  - Inpatient/residential treatment programs, where detoxification can be accomplished is an ideal setting for initiating naltrexone, but reduced access to such programs due to limited third party reimbursement
  - More rapid methods for naltrexone initiation are under development

Williams et al., 2017
Naltrexone Considerations: Adherence

- Treatment adherence can be challenging but this is better with long acting injectable formulation
  - Oral naltrexone generally not recommended for treatment of opioid use disorder, due to risk of non-adherence, relapse, and subsequent overdose
  - Long-acting injection naltrexone is preferred
  - Some patients experience subacute withdrawal symptoms after the first naltrexone injection.
    - Typically only occurs with the first injection and resolves within two weeks.
  - The treatment should include on going counseling, anticipatory guidance, motivational techniques emphasizing on adherence.
  - Involvement of a significant other may be helpful to support adherence.
  - Other than soreness at injection site, few other common side effects
  - Main safety concern is risk of relapse when injections are discontinued.
Medication-Assisted Treatment (MAT)

<table>
<thead>
<tr>
<th></th>
<th>Methadone</th>
<th>Buprenorphine (Oral)</th>
<th>Naltrexone (IM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Full Agonist on Opioid Receptor</td>
<td>Partial Agonist on Opioid Receptor</td>
<td>Antagonist on Opioid Receptor</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>80mg-100mg (Usual Dose)</td>
<td>4-32mg</td>
<td>380mg Depot Injection</td>
</tr>
</tbody>
</table>
| **Advantages**   | • Provided in a highly structured supervised setting where additional services can be provided on-site and diversion is unlikely  
                  • Maybe effective for individuals who have not benefited sufficiently from partial agonists or antagonists | • Improved safety due to partial agonism  
                  • Availability in office-based settings | • No addictive potential or diversion risk  
                  • Available in office-based settings  
                  • Option for individuals seeking to avoid any opioids |
Summary

- MAT is comprised of:
  - Methadone: A full agonist that activates the mu-receptor
  - Buprenorphine: A partial agonist that activates the mu-receptor at lower levels
  - Naltrexone: An antagonist that occupies the mu-receptor without activating it

- Ongoing treatment with MAT is effective at improving retention in treatment and decreasing use of illicit opioids. In contrast, short-term treatment where MAT is tapered after a brief period of stabilization have proven ineffective.

- Pharmacodynamically, combination of methadone or buprenorphine with other central nervous system depressants may increase the risk of sedation or respiratory depression and overdose. This risk is most clearly shown with benzodiazepines, particularly with intravenous use.
References


References


References


References


Patient Evaluation
Building a Therapeutic Alliance

- **Attitude**
  - Non-judgmental, curious, empathetic

- **Respectful**
  - Recognize adversity
  - Recognize strengths
  - Use the non-stigmatizing language

- **Honesty**

- **Shared goals**
  - Why is the patient seeking treatment?
  - Provider treatment team concerns

- **Reassurance**
  - Assure patient your objective is concern for his or her health
  - Confidentiality (with qualifiers)
    - Safety of self, well-being of other (especially children)

Goals Prior to Visit or During Visit

- Review Prescription Drug Monitoring Program (PDMP)

- Signed Forms:
  - Consent for treatment
  - Multi-Party Release, obtaining/releasing collateral information from/to all current or prior treatment teams
  - Treatment agreement

- Examples can be found at:
  - https://pcssnow.org/resources/clinical-tools/
Initial Urine Drug Screening for BUP/MAT Patients

- **Point of care testing**
  - Screening for:
    - Opiates
    - Marijuana
    - Cocaine
    - Amphetamines
    - Benzodiazepine
    - Alcohol bio-markers *

- **Confirmation**
  - On all new patients
  - On positive POC

- **Adjunctive Testing**
  - Pregnancy?
  - Fentanyl?
Medical History

- Review of current symptoms
- Review Medical History/Chronic Medical Problems
- Relationship of medical symptoms to substance use
- Treatments and response:
  - Medical/Surgical
- Obstetrics/Gynecology:
  - Pregnancies/Menstrual Status/Birth Control
- Dental care
- Medications:
  - Present/Past
  - Response/Side Effects
- Review of Labs, ECG
Psychiatric History

- Review of symptoms
- Relationship of psychiatric symptoms to substance use – establish temporality
- Prior diagnosis
- Trauma History
- Treatments and response:
  - Inpatient/Residential
  - Intensive Outpatient Programs (IOPs)/ Partial Hospitalization Programs (PHPs)
  - Outpatient
- Psychotropic medications
  - Present/Past
  - Response/Side Effects
Social and Family History

- Social history:
  - Birth and early development
  - Education:
    - Completing high school on time
  - Current employment status and prior occupations
  - Marital status, children, close supports
  - Living situation
  - Legal status? (No longer part of Dx)
  - Current Stressors, e.g. Housing/finance

- Family history:
  - Substance use disorders
  - Other psychiatric conditions
  - Other medical disorders
Substance Use History: Patterns

- Substance use history:
  - Ask about all substances:
    - Nicotine
    - Opioids: prescription opioids, non-prescribed opioids, heroin
    - Alcohol, marijuana
    - Hallucinogens, sedative/hypnotics, stimulants, other
Substance Use History: Patterns

- Substance use history:
  - Age at first use
  - Determine patterns of use over time:
    - Frequency
    - Amount
    - Route
  - Assess recent use (past several weeks)
  - Cravings and control:
    - Assess temporality and circumstances
    - Determine if patient sees loss of control over use
Substance Use History: Relapse/Treatment

- **Relapse/attempts to abstain:**
  - Determine if the patient has tried to abstain
    - What happened?
    - What helped?
  - Longest period of abstinence
  - Identify triggers to relapse

- **Treatment episodes:**
  - Response to treatment
  - Attitudes towards various treatment settings and mutual support groups (AA, NA etc.)
  - Length of abstinence
Substance Use History: Effects and Consequences

- Tolerance, intoxication, withdrawal:
  - Explain what is meant by tolerance
  - Determine the patient’s tolerance and withdrawal history
  - Ask about complications associated with intoxication and withdrawal

- Consequences of use:
  - Determine current vs past levels of functioning
  - Aberrant behaviors (e.g. sedation, deterioration in function)
  - Identify consequences:
    - Medical
    - Legal
    - Family
    - Psychiatric
    - Employment
    - Other
DSM V Criteria

• Loss of Control
  ▪ Larger amounts, longer time
  ▪ Inability to cutback
  ▪ More time spent, getting, using, recovering
  ▪ Activities given up to use.
  ▪ Craving
• Physiologic
  ▪ Tolerance
  ▪ Withdrawal
• Consequences
  ▪ Hazardous use
  ▪ Social or interpersonal problems related to use
  ▪ Neglected major roles to use
  ▪ Continued use after significant problems.

• A substance use disorder is defined as having 2 or more of these symptoms in the past year
• Tolerance and withdrawal alone don’t necessarily imply a disorder.
• Severity is related by the number of symptoms.

2-3 = mild
4-5 = moderate
6+ = severe
## Physical Examination

<table>
<thead>
<tr>
<th>System</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatologic</td>
<td>Abscesses, rashes, cellulitis, thrombosed veins, jaundice, scars, track marks, pock marks from skin popping</td>
</tr>
<tr>
<td>Ear, nose, throat, and eyes</td>
<td>Pupils pinpoint or dilated, yellow sclera, conjunctivitis, ruptured eardrums, otitis media, discharge from ears, rhinorrhea, rhinitis, excoriation or perforation of nasal septum, epistaxis, sinusitis, hoarseness, or laryngitis</td>
</tr>
<tr>
<td>Mouth</td>
<td>Poor dentition, gum disease, abscesses</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Murmurs, arrhythmias</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Asthma, dyspnea, rales, chronic cough, hematemesis</td>
</tr>
<tr>
<td>Musculoskeletal and extremities</td>
<td>Pitting edema, broken bones, traumatic amputations, burns on fingers</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hepatomegaly, hernias</td>
</tr>
</tbody>
</table>
## Laboratory Testing

<table>
<thead>
<tr>
<th>Baseline Labs</th>
<th>Recommended Labs (Case-by-Case and Provider Preference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy test (for women of child-bearing age)</td>
<td>Complete Blood Count (with differential) and platelet count</td>
</tr>
<tr>
<td>Urine Drug Screen</td>
<td>Serum Electrolytes</td>
</tr>
<tr>
<td></td>
<td>Hepatitis C&amp;A, HIV</td>
</tr>
<tr>
<td></td>
<td>Liver Function Tests (GGT, AST, ALT, PT or INR, albumin)</td>
</tr>
</tbody>
</table>
Factors to Consider in Determining OBOT Suitability

- Can the patient adhere with treatment requirements?
- Are the psychosocial circumstances of the patient stable and supportive?
- Is the patient taking other medications that may interact with buprenorphine, such as naltrexone, benzodiazepines, or other sedative-hypnotics?
- Are there resources available in the office to provide appropriate treatment? On-call coverage?
- Are there treatment programs available that will accept referral for more intensive levels of service if needed?
General Principles: Prior to starting OBOT

- First meeting/assessment can also be used to give the individual information about medication-assisted treatment:
  - Appropriate use of the medication; no sharing or diversion
  - The need to avoid continued drug and alcohol misuse
  - The need to inform physician if other medications are prescribed for any purpose
  - The need to store the medication safely; how will the patient do that?
Concurrent Substance Use and OBOT Suitability

- **Alcohol:**
  - Sedative-hypnotic
  - Patients should be cautioned to avoid alcohol while taking buprenorphine. Persons with active or current alcohol use disorders may require residential treatment prior to starting OBOT
  - **Note:** Essential to assess for use, intoxication, and withdrawal from sedative-hypnotics. If a patient is at risk for withdrawal seizures from alcohol or sedative-hypnotic use, buprenorphine will not control seizures

- **Use of other drugs (e.g. marijuana or cocaine):**
  - Not an absolute contraindication to buprenorphine treatment
  - Important to explore the reasons for continued use, willingness to abstain and document the discussion
OBOT and Concurrent SUDs and Non-prescribed Medication Use

- Other concurrent substance use disorders:
  - May benefit from completion of more intensive treatment such as Intensive Outpatient Programs or Residential Treatment prior to re-establishing care at OBOT

- Other Substance Use:
  - Buprenorphine is a treatment for opioid use disorder, not other drug use disorders. Does not directly impact cocaine/amphetamine use, cannabis use, alcohol use [though reductions may occur indirectly as a result of participating in monitored treatment]
  - Misuse of other drugs (such as stimulants or sedatives) can be prevalent among opioid-addicted persons and may interfere with overall treatment adherence
  - Also assess for misuse/overuse of other prescribed medications e.g. gabapentin
Before getting started with treatment:
- Make goals of treatment and expectations clear to patients
- Consider Obtaining multi-disciplinary Release

Use Treatment Agreements that outline terms of treatment:
- What the patient can expect from you and from treatment
- What you will expect/require from the patient
- Information for patients about buprenorphine and its safe use
- Informed consent (see Clinical Tools at www.pcssNOW.org)
- Know referral sources in the community if patients are unable to follow the treatment agreement and need more intensive care
- Example Agreement can be found in TIP(s) - 40 and 63:

SAMHSA, 2018
Treatment Agreements – Example of Key Components

- Arriving at appointments punctually
- Courteous in the office
- Refrain from arriving intoxicated or under the influence of drugs
- Agree not to sell, share, give any medication to others
- Agree not to deal, steal or conduct other illegal or disruptive activities
- Medications will be provided during scheduled office visits
- Responsible safe storage of medications
- Agree not to obtain medications from other providers, physicians, pharmacies, or other sources without informing my treating provider
- Agree to follow the prescription instructions
# Review of the Initial Evaluation

<table>
<thead>
<tr>
<th>Goals</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic Alliance</td>
<td>▪ Non-judgmental, understanding, respectful</td>
</tr>
<tr>
<td></td>
<td>▪ Use Language of recovery</td>
</tr>
<tr>
<td></td>
<td>▪ Shared goal-setting</td>
</tr>
<tr>
<td>Collateral Information</td>
<td>▪ Prescription Monitoring Programs</td>
</tr>
<tr>
<td></td>
<td>▪ Other Treatment Providers</td>
</tr>
<tr>
<td>Comprehensive Assessment</td>
<td>▪ Medical, Psychiatric, Review/Perform Lab Tests, Physical Exam</td>
</tr>
<tr>
<td>Signs of Withdrawal</td>
<td>▪ Clinical Opioid Withdrawal Scale (COWS)</td>
</tr>
<tr>
<td>Diagnostic Clarification of Substance Use Disorder</td>
<td>▪ DSM-Criteria with:</td>
</tr>
<tr>
<td></td>
<td>- Descriptor: Use Disorder; Intoxication; Withdrawal</td>
</tr>
<tr>
<td></td>
<td>- Specifiers: In Early remission; In Sustained remission;</td>
</tr>
<tr>
<td></td>
<td>In a controlled environment</td>
</tr>
<tr>
<td></td>
<td>- Severity: Mild, Moderate, Severe</td>
</tr>
<tr>
<td>Risk Assessment</td>
<td>▪ Active Suicidal Ideation; Homicidal Ideation; Overdose</td>
</tr>
<tr>
<td>Assessment of Appropriateness</td>
<td>▪ Buprenorphine Treatment (any contraindications)</td>
</tr>
<tr>
<td></td>
<td>▪ Is OBOT appropriate for patient at this time</td>
</tr>
<tr>
<td>Plan</td>
<td>▪ MAT; Therapy; Referrals; Safety Measures</td>
</tr>
</tbody>
</table>
Summary

- The initial evaluation is comprised of building a therapeutic alliance, obtaining data for treatment planning and initiation.

- Important components include History of medical, psychiatric and substance use disorders. There is great variability in practice and providers and clinics may have their own policies, protocols and preferences regarding the evaluation and documentation.

- Comprehensive physical exam can identify current state of health and areas for further evaluation and treatment.

- Office-Based Opioid Treatment (OBOT) can be appropriate for patients that are able to receive the level of care that can be provided in an outpatient setting. Some patients may benefit from stabilization offered by higher levels of care before engaging in office-based care.

- Methadone or Naltrexone-ER are other options for MAT and may be more suitable for patients who prefer either of these option or for whom OBOT is not effective or appropriate.
References


References


• Substance Abuse and Mental Health Services Administration. Medications To Treat Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 18-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018
Case Study #1: The Lawyer
Mr. Smith is a forty-year-old man who comes to your office asking to be treated with buprenorphine. He is a criminal defense attorney in private practice, and he knows about buprenorphine because you are treating some of his clients. His goal is to use buprenorphine during the week and occasionally use heroin (by snorting) on the weekend. He has used heroin for the past 5 years.

For the past 6 months, he has used heroin primarily on the weekend, but he is concerned now because he has begun to use small amounts of heroin daily. If he doesn’t use heroin, he gets loose stools, is irritable, and has difficulty getting and staying asleep. He has no desire to completely stop heroin use, but he doesn’t want to use it during the week.

His passion is playing jazz and he has organized a band. He says that heroin use is common in the club where his band plays. All the members of the band use heroin and many of his friends who come to the club also snort or inject heroin. He rarely buys heroin, as his friends usually give it to him.
His only other drug use is marijuana and alcohol (3-6 drinks/night on the weekend), again primarily used on the weekend. He has never been arrested or had significant medical consequences from his heroin use. He is not married. He has a 14-year-old son who he has supported and sees often.

• **What is the diagnosis?**

• **Is this patient a candidate for treatment with buprenorphine?**

• **What are the treatment goals?**

• **What is the initial treatment plan?**
Specialty Topics
Co-occurring Psychiatric Disorders

- 12.3 Million adults had SUD, no mental illness
- 7.9 Million adults had SUD and mental illness
- 35.6 Million adults had mental illness, no SUD
- 43.6 Million adults had mental illness

SAMHSA, 2017
Comorbid Psychiatric Disorders

• Distinguish between substance-induced disorders versus independent psychiatric disorders:
  ▪ Substance-induced:
    – Disorders related to the use of psychoactive substance; typically resolve with sustained abstinence
  ▪ Independent:
    – Disorders which present during times of abstinence; symptoms not related to use of psychoactive substance

**Note:** There is no specific period of time used to differentiate these disorders
Substance-Induced Disorders

- Symptoms occur only when misusing drugs
- Symptoms are related to intoxication, withdrawal, or other aspects of active use
- Onset and/or offset of symptoms is preceded by increases or decreases in substance use
- Goals:
  - Sustained abstinence
  - Re-evaluation
Independent Disorders

• Symptoms occur when not using or misusing psychoactive substances, or with steady use without change in amount or type
• Family history may point to independent disorder if present in first degree relatives
• Goal:
  ▪ Cessation of substance use, and treatment of psychiatric symptoms
Depressive and Anxiety Symptoms

- Depressive and anxiety symptoms are common at treatment entry
- Symptoms may resolve within few days of stable treatment
- Symptoms that persist beyond acute intoxication and withdrawal can be worthwhile targets for treatment:
  - For example, with Selective Serotonin Reuptake Inhibitors
- Patients treated with MAT respond to medications for depression and anxiety at rates similar to those without opioid use disorders
Treatment of Co-Occurring Psychiatric Disorders

- Avoid use of benzodiazepines
  - Risk of misuse
  - Interactions with buprenorphine possible
  - First-Line Treatments for anxiety and depression
    - Selective Serotonin reuptake inhibitors
    - Psychotherapy (e.g.: cognitive behavioral therapy)

- Stimulants
  - Obtain collateral information from Prescription Drug Monitoring Program, Psychiatric and/or Primary Care Provider
  - If there is concern for Attention Deficit Hyperactivity Disorder (ADHD), consider Adult ADHD Self-Report Scale (ASRS) or refer patient to a Psychiatric or Primary Care Provider for assessment
  - Continue stimulants if they have been legitimately prescribed by Psychiatric or Primary Care Provider

Chang et al., 2005
Kampman et al., 2015
Factors to Consider in treating OUD in the Pregnant Patient

- Pregnancy:
  - If patient elects to start or to stay on buprenorphine
    - Document informed consent for ongoing treatment with buprenorphine.
    - Obtain consent for release of information and inform patient’s Ob/Gyn that patient is on buprenorphine.
    - Consider starting with or switching to equivalent dose of buprenorphine mono-product (available as a generic medication)
  - If methadone is selected refer to OTP and may start without a period of mild withdrawal.
    - Administer split dose (e.g.: 30 mg on day 1 in two divided doses, and increase as clinically indicated).
Use of Buprenorphine With or Without Naloxone in the Pregnant Patient

- **Buprenorphine/Naloxone:**
  - FDA designates naloxone as Pregnancy Category B (the formulation of buprenorphine-naloxone is Category C):
    - No known teratogenic effects in animals
    - Controlled studies have not been conducted in humans
  - Increasing evidence that buprenorphine-naloxone may be safe in pregnancy
  - However, buprenorphine *without* naloxone is recommended for pregnant, opioid-dependent women

- **Postpartum:**
  - Transition to original pre-pregnancy dose and formulation
  - Mothers taking buprenorphine are safe to breastfeed

Lund et al., 2013
Pregnancy and Methadone Treatment

- Formally first-line tx. Commonly used for pregnant women with OUD
- Titrate dose to effectively reduce cravings
- Medication changes:
  - Second and third trimester:
    - Doses may need to **increased** due to increased metabolism and circulating blood volume
    - Doses may need to be split
  - With advancing gestational age: Plasma levels of methadone progressively decrease and clearance increases
    - Increasing or splitting the methadone into 12-hour doses may produce less cravings and withdrawal

Kampman et al., 2015
Buprenorphine vs. Methadone in Pregnant Patients with OUD

<table>
<thead>
<tr>
<th>Buprenorphine (Mono Product)</th>
<th>Methadone</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Similar efficacy as methadone</td>
<td>- More structure- better for patients in unstable situations</td>
</tr>
<tr>
<td>- Same rates of adverse events, NAS, as methadone</td>
<td>- Decreased risk of diversion</td>
</tr>
</tbody>
</table>
| - Improvement over methadone:  
  - Lower risk of overdose  
  - Fewer drug interactions  
  - Milder withdrawal symptoms in NAS  
  - Reduced morphine dosing  
  - Significantly shorter hospital stay | - More long-term data on outcomes |

Fischer et al., 1998, 1999  
Jones et al., 2010;  
Kakko et al., 2008;  
Kraft et al., 2017
Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study

Jones et al., 2010
Factors to Consider in Treating the Adolescent OUD Patient

- The American Academy of Pediatrics (AAP) advocates for increasing resources to improve access to medication-assisted treatment of opioid-addicted adolescents and young adults.
  - Increase resources for medication-assisted treatment within primary care and access to developmentally appropriate substance use disorder counseling in community settings.
  - The AAP recommends that pediatricians consider offering medication-assisted treatment to their adolescent and young adult patients with severe opioid use disorders or discuss referrals to other providers for this service.
- Buprenorphine is approved for use in patients 16y/o and older.
- Naltrexone and methadone are approved for patients 18y/o and above.
- Protocols for initiation and treatment are similar to the adult.
- Encourage looking for adolescent based programs in the community.
Different Approaches:

- Initially try non-opioid analgesics (ketorolac or NSAIDs)
- Continue **same** buprenorphine maintenance dose but add non-opioid analgesics
- Use **split dose** for concurrent pain and dependence
  - Buprenorphine’s analgesic duration is only a few hours
- Stop buprenorphine and initiate full agonist therapy
Perioperative Management

- **General:**
  - Patients fear mistreatment, Providers fear deception
  - Lack of consensus in the field
    - often based on the preference of the surgical/anesthesia teams

- **Pre-Op:**
  - Confirm Multi-Party Consent and Coordination of care with providers
  - If patient is already on Partial Agonist:
    - Take last Buprenorphine maintenance dose 24-hours prior to surgery
    - Higher dosing of short-acting opioids may be required post-surgical

Merrill et al., 2002
Wenzel et al., 2016
Post Op Options for Patients already on Buprenorphine

<table>
<thead>
<tr>
<th>Options</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Continue Full Agonist and then Transition to Partial Agonist:</td>
<td>▪ Consider using Extended Release/Long Acting with Immediate Release/Short Acting for breakthrough pain</td>
</tr>
<tr>
<td></td>
<td>▪ Discussions about risks of relapse</td>
</tr>
<tr>
<td></td>
<td>▪ Medication security</td>
</tr>
<tr>
<td>▪ Continue Partial Agonist with:</td>
<td>▪ More frequent dosing</td>
</tr>
<tr>
<td></td>
<td>▪ Consideration for Increased total dosage</td>
</tr>
<tr>
<td></td>
<td>▪ Have a clear and detailed discussion with patient about a return to baseline dosing – specify timeline of changes for clarity</td>
</tr>
</tbody>
</table>

Merrill et al., 2002
Wenzel et al., 2016
# Acute Pain Management for Patients currently on Naltrexone

<table>
<thead>
<tr>
<th>Clinical Scenario</th>
<th>Management Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild Pain</td>
<td>- Non-Opioid options e.g. Full doses of NSAIDs (e.g. ketorolac injection)</td>
</tr>
<tr>
<td>Elective Surgery</td>
<td>- Make a plan and schedule surgery. For patients on:</td>
</tr>
<tr>
<td></td>
<td>- <strong>Oral Naltrexone</strong>: Discontinue at least 72 hours after last dose</td>
</tr>
<tr>
<td></td>
<td>- <strong>Extended Release Naltrexone</strong>: At least four-weeks after receiving injection</td>
</tr>
<tr>
<td>Major Pain or Emergency</td>
<td>- Regional anesthesia</td>
</tr>
<tr>
<td></td>
<td>- Conscious sedation</td>
</tr>
<tr>
<td></td>
<td>- General anesthesia <strong>[Note: High potency opioids like fentanyl can override blockade]</strong></td>
</tr>
</tbody>
</table>
Chronic Pain Patients

- Consider consulting a pain medicine specialist
- Consider Multidisciplinary Team Approach
- Try non-opioid and adjuvant analgesics
- Consider non-pharmacologic therapies
CYP 3A4 is the primary hepatic enzyme involved in metabolism of both methadone and buprenorphine.

Many anti-retrovirals affect buprenorphine or methadone levels and in some cases buprenorphine or methadone levels affect anti-retrovirals levels.

There are markedly fewer drug/drug interactions with buprenorphine and anti-retrovirals as compared to methadone and little or no interactions with naltrexone.

Providers should consider referral to specialized HIV treatment programs and services – if available.

CSAT, 2004
McCance-Katz et al., 2010
Moatti et al., 2000
Montoya et al., 1995
Patients with Renal Failure

- Suitable to use buprenorphine in patients with renal failure
- No significant difference in kinetics of buprenorphine in patients with renal failure versus healthy controls
- No significant side effects in patients with renal failure
- Buprenorphine and methadone can be prescribed to patients undergoing hemodialysis
Patients with Compromised Hepatic Function

- Buprenorphine undergoes hepatic metabolism, primarily by the CYP450 3A4 system
- Patients with compromised hepatic function could have reduced metabolism of buprenorphine, with resultant higher blood levels of the medication
- No specific hepatotoxicity has been demonstrated for either methadone or buprenorphine
- Patients with impairments in hepatic function should be monitored closely
  - Moderately elevated levels (>3 times the upper limit of normal) should be monitored.
Summary

- Approximately 40% of adults with SUD had a co-occurring psychiatric disorder. Diagnosis and Treatment of mental health issues can potentially have a positive impact on Opioid Use Disorder (OUD).

- Methadone has historically been considered first-line treatment of OUD in pregnant women. However, Increasing evidence is demonstrating that Buprenorphine without naloxone is well-tolerated and efficacious with potential benefits for the newborn.

- Although Buprenorphine is approved for individuals over 16 years of age and Methadone is approved for individuals over 18 years of age providers can consider Naltrexone ER in combination with psychosocial treatment options for adolescents with OUD.
Summary

- Peri-operative pain management practices for patients with OUD are variable and require close coordination with surgical team.
- There are markedly fewer drug/drug interactions with Buprenorphine and antiretrovirals as compared to methadone.
- Buprenorphine is suitable to use in patients with renal failure.
- Unless the patient has acute hepatitis, pharmacotherapy with methadone or buprenorphine is not contraindicated on the basis of mildly elevated liver enzymes.
References


• Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons with HIV/AIDS. Treatment Improvement Protocol (TIP) Series, Number 37. Rockville, MD: Center for Substance Abuse Treatment, 2000.

References


References


References


References


• Smith, K. and Lipari, R.N. Women of childbearing age and opioids. The CBHSQ Report: January 17, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD.


References


Medication Assisted Treatment
Clinical Application
Clinical Uses of Buprenorphine

- Induction
- Stabilization and Maintenance
- Withdrawal
Buprenorphine Induction
Rationale

- Goals of buprenorphine initiation:
  - Identify dose of buprenorphine at which the patient:
    - Discontinues or markedly reduces use of other opioids
    - Significantly decreased or absent withdrawal symptoms
    - Has minimal/no side effects
    - Experiences decreased cravings
Buprenorphine Formulations

- Choice of formulations is based on:
  - Insurance/Third party payer considerations
  - Patient preferences
  - Safety
  - Decreased Diversion potential

- Formulations:
  - Buccal film; Sublingual films
  - Tablets
  - Subdermal implants
  - Depot formulation given as a subcutaneous injection

- All of the approved forms have demonstrated similar efficacy for treating opioid use disorder

- Buprenorphine for transdermal (via patch) and intravenous (via injection) use are available for analgesic use. They were tested but not approved for treating opioid use disorder

SAMHSA, 2016, 2016
# Buprenorphine Formulations for Opioid Use Disorder

<table>
<thead>
<tr>
<th>Content</th>
<th>Route</th>
<th>Products</th>
<th>Available Doses</th>
<th>Equivalent Dose to 8mg Buprenorphine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>With Naloxone</strong></td>
<td>Sublingual</td>
<td>Film (Suboxone)</td>
<td>2mg Bup/0.5mg Nx 4mg Bup/1mg Nx 8mg Bup/2mg Nx 12mg Bup/3mg Nx</td>
<td>8mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet - Generic</td>
<td>2mg Bup/0.5mg Nx 8mg Bup/2mg Nx</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sublingual</td>
<td>Tablet - (Zubsolv®)</td>
<td>1.4mg Bup / 0.36mg Nx 2.9mg Bup / 0.7mg Nx 5.7mg Bup / 1.4mg Nx 8.6mg Bup / 2.1mg Nx 11.4mg Bup / 2.6mg Nx</td>
<td>5.7 mg</td>
</tr>
<tr>
<td></td>
<td>Buccal</td>
<td>Film (Bunavail®)</td>
<td>2.1mg Bup / 0.3mg Nx 4.2mg Bup / 0.7mg Nx 6.3mg Bup / 1mg Nx</td>
<td>4.2mg</td>
</tr>
<tr>
<td><strong>Mono-product</strong></td>
<td>Sublingual</td>
<td>Tablet - Generic</td>
<td>2mg Bup 8mg Bup</td>
<td>8mg</td>
</tr>
<tr>
<td></td>
<td>Implant</td>
<td>Probuphine (Four implants for six-months in one arm)</td>
<td>74.2mg</td>
<td>74.2 mg</td>
</tr>
<tr>
<td></td>
<td>Injection</td>
<td>Sublocade (Once-monthly injection)</td>
<td>100mg, 300mg</td>
<td>300 mg: First dose 100mg: Steady state dose</td>
</tr>
</tbody>
</table>
Buprenorphine Induction
First Prescription

- Many Logistical Factors/Considerations
  - Review that patient meets induction criteria
  - Insurance
  - Confirm access to pharmacy
  - Confirm access to urine drug testing

- Location
  - Office Induction:
    - Patient given prescription and brings medication to the office
  - Home Induction:
    - Patient goes home with instructions, follow-up appointment, and a prescription for medicine
Office Buprenorphine Induction
Day #1

- **Timing**
  - Some offices prefer inductions earlier in the week – Consider Monday, Tuesday and avoid Fridays
  - Consider scheduling office induction earlier in the day

- Decrease likelihood of precipitated withdrawal at induction by:
  - Ensuring mild to moderate withdrawal at the time of induction
    - Document using Clinical Opiate Withdrawal Scale (COWS)
  - Start with low dose: 2-4mg equivalents
Clinical Opiate Withdrawal Scale (COWS)

- Resting Pulse
- Sweating
- Restlessness
- GI Upset
- Tremor

- Pupil Size
- Bone or Joint Aches
- Yawning
- Anxiety or Irritability
- Gooseflesh
- Runny Nose or Tearing Eyes

Wesson and Ling, 2003
# Clinical Opiate Withdrawal Scale (COWS)

For each item, circle the number that best describes the patient’s signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increase pulse rate would not add to the score.

<table>
<thead>
<tr>
<th>Patient’s Name: ___________________________</th>
<th>Date and Time <strong>/</strong>/__</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reason for this assessment: ________________</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resting Pulse Rate: _______ beats/minute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measured after patient is sitting or lying for one minute</td>
</tr>
<tr>
<td>0 pulse rate 80 or below</td>
</tr>
<tr>
<td>1 pulse rate 81-100</td>
</tr>
<tr>
<td>2 pulse rate 101-120</td>
</tr>
<tr>
<td>4 pulse rate greater than 120</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GI Upset: over last 6 hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 no GI symptoms</td>
</tr>
<tr>
<td>1 stomach cramps</td>
</tr>
<tr>
<td>2 nausea or loose stool</td>
</tr>
<tr>
<td>3 vomiting or diarrhea</td>
</tr>
<tr>
<td>5 Multiple episodes of diarrhea or vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sweating: over past 6 hour not accounted for by room temperature or patient activity:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 no report of chills or flushing</td>
</tr>
<tr>
<td>1 subjective report of chills or flushing</td>
</tr>
<tr>
<td>2 flushed or observable moistness on face</td>
</tr>
<tr>
<td>3 beads of sweat on brow or face</td>
</tr>
<tr>
<td>4 sweat streaming off face</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tremor: observation of outstretched hands</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 No tremor</td>
</tr>
<tr>
<td>1 tremor can be felt, but not observed</td>
</tr>
<tr>
<td>2 slight tremor observable</td>
</tr>
<tr>
<td>4 gross tremor or muscle twitching</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Restlessness Observation during assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 able to sit still</td>
</tr>
<tr>
<td>1 reports difficulty sitting still, but is able to do so</td>
</tr>
<tr>
<td>3 frequent shifting or extraneous movements of legs/arms</td>
</tr>
<tr>
<td>5 Unable to sit still for more than a few seconds</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yawning Observation during assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 no yawning</td>
</tr>
<tr>
<td>1 yawning once or twice during assessment</td>
</tr>
<tr>
<td>2 yawning three or more times during assessment</td>
</tr>
<tr>
<td>4 yawning several times/minute</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pupil size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 pupils pinned or normal size for room light</td>
</tr>
<tr>
<td>1 pupils possibly larger than normal for room light</td>
</tr>
<tr>
<td>2 pupils moderately dilated</td>
</tr>
<tr>
<td>5 pupils so dilated that only the rim of the iris is visible</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anxiety or Irritability</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 none</td>
</tr>
<tr>
<td>1 patient reports increasing irritability or anxiousness</td>
</tr>
<tr>
<td>2 patient obviously irritable anxious</td>
</tr>
<tr>
<td>4 patient so irritable or anxious that participation in the assessment is difficult</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bone or Joint aches / if patient was having pain previously, only the additional component attributed to opiate withdrawal is scored</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 not present</td>
</tr>
<tr>
<td>1 mild diffuse discomfort</td>
</tr>
<tr>
<td>2 patient reports severe diffuse aching of joints/ muscles</td>
</tr>
<tr>
<td>4 patient is rubbing joints or muscles and is unable to sit still because of discomfort</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gooseflesh skin</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 skin is smooth</td>
</tr>
<tr>
<td>3 piloeruption of skin can be felt or hairs standing up on arms</td>
</tr>
<tr>
<td>5 prominent piloeruption</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Runny nose or tearing Not accounted for by cold symptoms or allergies</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 not present</td>
</tr>
<tr>
<td>1 nasal stuffiness or unusually moist eyes</td>
</tr>
<tr>
<td>2 nose running or tearing</td>
</tr>
<tr>
<td>4 nose constantly running or tears streaming down cheeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Score __________</th>
</tr>
</thead>
<tbody>
<tr>
<td>The total score is the sum of all 11 items</td>
</tr>
</tbody>
</table>

| Initials of person completing Assessment: ____________________________ |

Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal
Office Buprenorphine Induction
Patient Education

- Sublingual tablets and films must be held under the tongue several minutes to dissolve
- Buccal delivery films take fewer minutes to dissolve and are stuck to the buccal mucosa

**Instruct to:**
- Start with a moist mouth, avoid acidic drinks (coffee or fruit juice)
- Avoid using nicotine products as this interferes with absorption
- Avoid speaking with the sublingual medication
- Keep dissolving medicine under tongue
- After medication is completely dissolved, leave in mouth an additional 5 min before swallowing or spitting remaining sputum
Buprenorphine Induction
Day #1

If patient is not in opioid withdrawal on arrival in office:

- Assess and confirm time of last opioid use
- Have patient wait in the office until you see evidence of withdrawal
  
  OR

- Consider home induction
Office Buprenorphine Induction
Day #1

- Instruct the patient to abstain from any opioid use for a minimum of:
  - 12-16 hours for short-acting opioids
  - 24 hours for sustained-release opioid medications
  - 36 hours for methadone

- Observe and document Mild vs. Moderate withdrawal:
  - **NOTE:** Be aware of Fentanyl; do not induce unless moderate withdrawal (COWS 13 to 15) is observed
Office Buprenorphine Induction
Day #1 – Short Acting Opioids

- Patients dependent on short-acting opioids (e.g. heroin/oxycodone/hydrocodone):
  - Instruct patient to abstain from any opioid use for 12 to 24 hours prior to induction visit:
    - Arrive in mild-moderate withdrawal at induction visit
  - Use opioid withdrawal scale (COWS > 8):
    - Document and assess severity of withdrawal
    - Track the patient’s response to first day’s dose
Office Buprenorphine Induction
Day #1 – Methadone

- Do not start buprenorphine until the patient manifests signs of opioid withdrawal
  - Waiting at least 36 hours reduces risk of precipitated withdrawal
  - Lower doses of buprenorphine/naloxone are less likely to precipitate methadone withdrawal.\textsuperscript{328}
    - For example, once opioid withdrawal is verified, an initial dose of 2 mg/0.5 mg can be given. If patients continue to have unrelieved opioid withdrawal after the first 2 mg dose, administer another 2 mg/0.5 mg dose approximately every 2 hours as needed (holding for sedation)
  - Induction should be conducted slowly; consider treating unrelieved withdrawal symptoms with nonopioid therapies as needed
  - Be alert to any increase in withdrawal symptoms, as this may suggest precipitated withdrawal.
First dose: 2-4 mg SL buprenorphine/naloxone

Monitor in office for 2+ hours after first dose
  - Relief of opioid withdrawal symptoms should begin within 30-45 minutes after the first dose

Re-dose every 2-4 hours, if opioid withdrawal subsides then reappears

Stabilize at dose that eliminates craving; typical dose range from 8 mg to 16 mg

Gradually increase dose after establishment of a steady state over as needed for continued craving.
  - Note: This can be increased more rapidly if the patient has a lot of craving.
Buprenorphine Induction
Day #1

- If opioid withdrawal appears shortly after the first dose buprenorphine may have precipitated a withdrawal syndrome.

- Greatest severity of buprenorphine-related precipitated withdrawal in the first few hours (1-4) after a dose, with a decreasing (but still present) set of withdrawal symptoms over subsequent hours.
Precipitated Withdrawal Management

- If a patient has precipitated withdrawal consider:
  - Giving another dose of buprenorphine, attempting to provide enough agonist effect from buprenorphine to suppress the withdrawal
  
  OR

  - Stopping the induction, provide symptomatic treatments for the withdrawal symptoms, and have patient return the next day

Since the latter risks losing the patient, the first option is preferred.
Home Induction
Multiple Approaches but Subtle Clinical Variance

- Similar outcomes noted for observed and home induction in terms of safety and efficacy

- Process:
  - Teach patient about how bup/nx works and how it is absorbed
  - Review typical withdrawal symptoms with patient
    - Start assessing withdrawal symptoms 12 hours after short-acting opioids and 24 - 36 hours after last illicit methadone use
    - Self administer 2mg bup/nx when experiencing withdrawal symptoms
    - Self assess again in 1-3 hours. If still withdrawing, self administer another 2mg dose
  - May repeat until a maximum total dose of 8-12mg during first day
Home Induction Instructions

Day #2

- **Day #2:** Continue dose established on Day #1
  - Encourage patient to preferably take Day #1 dose on the morning of Day #2
  - Encourage office staff to contact patient on Day #2 to assess dose response
  - After contact with patient there may be reason for additional dose adjustments:
    - If patient feels well, instruct patient to continue Day #1 dosing
    - If patient is experiencing cravings or discomfort consider increasing dose by 2-4 mg
    **OR**
    - discuss relapse prevention and assure patient that discomfort will stabilize over time
- Avoid rapid dose adjustments
Buprenorphine Induction
Day #2 and Beyond

- Stabilization will occur for most patients between 8 to 16mg per day:
  - Most individuals do not need more than 16mg per day but occasionally higher doses may be needed for persistent symptoms/ongoing opioid use
    - Most insurance companies limit daily doses to 24 mg
    - Though there is approval for a maximum dose of 32mg, doses above 24mg may increase risk of diversion
  - Note – If there are concerns for diversion:
    - Consider more intensive monitoring [E.g. more frequent urine testing, shorter prescription durations, supervised dosing]
Stabilization and Maintenance

• Continue to reassess patient technique in medication administration:
  • Usual administration of buprenorphine/naloxone dosing is daily however preferably no more than twice-daily dosing
  • For proper absorption, no more than two film strips or two tablets should be taken at once

• Adjust daily dose by increments of 2-4 mg as needed:
  • Increase primarily for persistent cravings
How Long Should Buprenorphine Maintenance Be?

Evidence is variable

- Studies as long as 16 weeks show high relapse rates with medication withdrawal
- Improved retention rates in treatment with extended buprenorphine maintenance

Continue maintenance as long as patient is benefitting from treatment (decreased substance use, meeting employment, educational, relationships goals):

- Note: Provider can have discussions regarding reduction in dose with improving stability or patient preference however:
  - Caution patients about discontinuing medication too early in treatment

Kakko et al., 2003
Weiss et al., 2011
Optimal Duration of MAT

proportion of days when buprenorphine was taken

14% fewer ED visits
18% fewer admissions

months since starting treatment

Lo-Ciganic et al., 2016
Treatment Retention and Buprenorphine Dosage

Fiellin et al., 2014
Medically Supervised Withdrawal from Full-opioid Agonist Using Buprenorphine

- Buprenorphine suppresses opioid withdrawal symptoms
- When stopping buprenorphine:
  - A more gradual taper decreases the severity of withdrawal symptoms
  - Taper durations ranging from 4 to 30 days are common in clinical practice
- Withdrawal symptoms may not occur until 2-3 days after stopping buprenorphine
- Adjunctive medications (E.g. clonidine) to manage symptoms supportively

Ling et al., 2009
Sigmon et al., 2013
XR-NTX Practical Considerations

- **Logistics**
  - Adequate insurance or program coverage
    - Out of pocket XR-NTX is ~ $1100/dose
    - Ordered from specialty pharmacy, shipped to physician
    - Keep refrigerated until dosing visit

- **Check Opioid free status of patient by self-report and verified by urine drug screen**

- **Consider administering Naloxone challenge before first dose**
  - **OR**

- **Preload oral Naltrexone**
XR-NTX Considerations

- XR-NTX injection
  - Side Effects
    - Opioid blockade may interfere if acute pain management is needed
    - Headaches, nausea, flu-like: common with 1st injection, but not subsequent injections
    - Injection site pain: common
Naltrexone Initiation

- Naltrexone is an opioid receptor antagonist and can only be started in individuals who are completely free of opioids.

- Official prescribing information for injection naltrexone recommends 7-10 days “washout” period between the two phases: last dose of opioid and first dose of NTX.

- When naltrexone is given to patients who are physically dependent, or have opioids in their system, naltrexone will displace opioids off the receptor and withdrawal symptoms will rapidly emerge.
  - Precipitated withdrawal as opposed to a slow onset of a spontaneous withdrawal can look atypical and can involve delirium.
# Medically Supervised Withdrawal

## Approach

<table>
<thead>
<tr>
<th>Symptomatic-only treatment</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A variety of adjunctive medications are used to decrease specific symptoms of withdrawal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rapid medically supervised withdrawal using antagonist</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Naltrexone is added few (3-4, days after the last dose of opioid starting with very low doses (3-6 mg) Emerging withdrawal symptoms are treated with adjunctive medications to minimize discomfort</td>
</tr>
</tbody>
</table>
Acute Withdrawal Using Buprenorphine

- Buprenorphine suppresses opioid withdrawal symptoms
- Long-term efficacy of medical withdrawal with buprenorphine is not known.
- Studies of other withdrawal treatments have shown that brief withdrawal periods are unlikely to result in long-term abstinence unless one plans on initiating naltrexone.
Acute Withdrawal Using Buprenorphine

- Withdrawal can be primary treatment or termination of period of maintenance therapy
- Many regimens can be used based on clinical practice and patient needs
- Example: Withdrawal over 3 days:
  - First day: 8/2-12/3 mg s.l.
  - Third (last) day: 6/1.5 mg s.l.
- Can extend taper by 2-3 days if patient has trouble tolerating the procedure; offer reassurance and treat emerging insomnia, anxiety, and/or myalgias
- Withdrawal symptoms may not occur until completely off drug for 2-3 days
Adjunctive Medication Options During Medically Supervised Withdrawal

<table>
<thead>
<tr>
<th>Withdrawal Symptoms</th>
<th>Adjunctive Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety/restlessness</td>
<td>▪ a-2 Adrenergic agonists (e.g. clonidine)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>▪ Sedating antidepressants (e.g. trazadone)</td>
</tr>
<tr>
<td>Musculo-skeletal pain</td>
<td>▪ Acetaminophen, Ibuprofen</td>
</tr>
<tr>
<td>GI Distress (nausea, vomiting, diarrhea)</td>
<td>▪ Oral hydration</td>
</tr>
<tr>
<td></td>
<td>▪ Antiemetics (e.g. ondansetron)</td>
</tr>
<tr>
<td></td>
<td>▪ Anti-diarrheals (e.g. loperamide)</td>
</tr>
</tbody>
</table>
α₂-Adrenergic agonists

- **Clonidine**
  - Administer 0.1 mg as needed for symptoms of withdrawal every 6 hours
  - Assure continuous hydration (juice>water)
  - Medication reduces physical withdrawal but not craving for opiates
  - Side-effects are sleepiness, dizziness, fainting, headache
Protracted Withdrawal: Naltrexone Flu

- Patients who start naltrexone right after medically supervised withdrawal commonly experience “flu-like” symptoms that are consistent with subacute opioid withdrawal
  - Somatic complaints: insomnia, GI distress, hyperalgesia, anergia
  - Anxiety, irritability, dysphoria, anhedonia
  - Symptom severity correlated with naltrexone dose
  - Severity may be lower if naltrexone initiation is postponed (but relapse risk)

- Partially alleviated with aggressive symptomatic treatment

- Most of these symptoms remit by 2 weeks
  - Unusual for these symptoms to occur after 2\textsuperscript{nd} and subsequent injections
Initiating IM Naltrexone (XR-NTX)

Summary

- Effective suppression of withdrawal symptoms, accomplished with a range of adjunctive medications, is essential to the success

- Effective method will balance the degree of discomfort and the duration of treatment

- Ability of the team to expect and respond to emerging complications, to maintain enthusiasm as confidence in the method can influence outcome

- Anticipatory guidance and motivational techniques should accompany the initiation of treatment with XR-NTX to improve long-term adherence as many patients will experience internal barriers to continuation

Sigmon et al., 2012
Case Study #2: The Teacher
Robert, a 35-year old teacher
Considering Treatment Options

The patient is a 35-year-old school teacher. He has been injecting heroin on and off since he was 16. He has never been arrested. He has been through many episodes of heroin detoxification, mostly outpatient methadone detoxification but has also been in three inpatient drug treatment programs. The last inpatient program was a 28-day, drug-free recovery program, and he remained both heroin and alcohol free for about 6 months following treatment. He teaches math at a junior high school and is in some difficulty because of “calling in sick too much.” His wife is in recovery, and insisted that he return to treatment after she discovered he was taking large quantities of codeine pills from several doctors for a back injury following an automobile accident. She is unaware that he is also injecting heroin at least once daily. He has been alcohol abstinent for the past two years. His only current medical problem is that he is hepatitis C positive and he has been so for at least 10 years.

He states “Doc, I know I’m an addict. My wife cleaned up when she was pregnant with our daughter, and she just got her 12-year chip. She moved on with her life, but I’m stuck. My back injury threw me into a tailspin. At first, I really needed the codeine, but now I’m just using them to stave off heroin withdrawal. I really need your help. If my wife finds out I’m back on the needle, she’ll leave me this time.”
Case #2: Robert, a 35-year old teacher

- Does this patient meet DSM-5 criteria for opioid dependence?
- What are the treatment options for this patient?
- How would you assess the need for pharmacotherapy for this patient?
- Is this patient a candidate for buprenorphine?
Urine Drug Testing
General Goals of Drug Testing in Office-Based Treatment

- Important and routine component of treatment
- Urine testing can be viewed as a means for helping the provider to help the patient
- Testing is not meant to "catch" the patient, and a positive test result should not simply lead to discharge from treatment, but an opportunity for reviewing the patient’s Recovery Management
Drug Testing in Office-Based Treatment Specifics

- Laboratory testing for evidence of substance use has several roles in office-based treatment for opioid use disorder, including:
  - Initial assessment
  - Treatment planning
  - Screening to identify non-prescribed substances/medications
  - Monitoring adherence to pharmacotherapy
  - Evaluating efficacy of treatment and assist in treatment planning

- Ideally laboratory testing should be:
  - Random
  - Observed
  - Convenient for the patient
  - High quality
  - Able to offer timely result
Screening and Confirmatory Tests

- A common clinical approach:
  - Test for a panel of commonly-used substances using screening tests
  - Then to perform confirmatory tests for:
    - Positive results whose accuracy is important for treatment planning
    - Periodic general screening assessing commonly used substances that are not evident on POCT
    - Identification of prescribed medications or metabolites

- Confirmatory testing is not necessary at every visit

DuPont et al., 2013
Moeller et al., 2017
SAMHSA, 2012
Common Tests

Some commonly-used screening tests include:

- Benzodiazepines
- Cannabinoids
- Amphetamines
- Cocaine metabolite (benzoylecgonine)
- Opiates (detects morphine, codeine, and metabolites)

Less commonly-used screening tests include:

- Alcohol metabolite (ethyl glucuronide or ethyl sulfite)
- Buprenorphine
- Fentanyl
- Oxycodone
- Methadone

*these and other synthetic opioids require specific tests—they are not detected by the test for opiates*

Moeller et al., 2017
Testing for Buprenorphine

- Testing for buprenorphine during MAT can be useful to monitor adherence and detect possible diversion.
- Confirmatory testing will distinguish buprenorphine and its metabolite, norbuprenorphine, which is usually present in greater concentrations.
- Individuals vary in the ratio of buprenorphine to norbuprenorphine due to individual metabolism and co-administered inducers or inhibitors of CYP3A4.
- Buprenorphine with little or no metabolite (i.e. a ratio of norbuprenorphine:buprenorphine: < 0.02) suggests that buprenorphine was added to the urine.

Sethi & Petrakis, 2013
Hull et al., 2008
References


References


References


Case Study #3: The Student
A 19-year-old woman university student comes to you asking for treatment of her heroin use. She has been using heroin intranasally for the last 15 months, daily for the last 3 months. She is now using about 1 gram daily. Some of her friends are now switching to intravenous use because it takes less heroin to keep from getting sick. She says she does not want to do that but may be “forced” to because she cannot keep paying the “extra cost” of nasal use. She has used all the money her parents gave her for school expenses to buy heroin, her credit cards are maxed out, and she has borrowed money from her friends. Until last semester, she had an overall B average, but this semester she is in academic difficulty. When she doesn’t use heroin, she has muscle aches, diarrhea, insomnia, and anxiety. She recognizes the symptoms as heroin withdrawal and was surprised because thought she could not develop dependence with nasal use. She has no prior history of drug treatment.
19-year-old university student
Clinical Management - Part I

- What is the diagnosis?
- Is this patient a candidate for treatment with buprenorphine?
- What are the treatment goals?
- What is the initial treatment plan?
The clinic physician gives her a prescription for 6 day supply of buprenorphine (4 mg/day), and she is told to participate in the clinic’s relapse prevention workshop six days a week and to schedule individual counseling at the clinic once a week.

She returns 3 days later having taken 8 mg/day for 3 days. She has not attended the relapse prevention workshop nor scheduled an individual counseling session. The counselor is not available to see her when she comes.

• **What is the treatment plan at this point?**
She returns the following day at a time when neither the group nor the counselor is available. She is told she has to attend the relapse prevention workshop in order to get medication. She does not return to the clinic for 4 weeks. When she does, she is smoking more heroin than before, but having no difficulty with finances because she has dropped out of school and is working as a stripper at a local “gentlemen’s club.”

• **What would you recommend at this point?**
BUPRENORPHINE Waiver Notification Form

Entering a 30 Patient Notification
Submitting a 30 Patient Notification Form Online

Before you begin
Before starting this application, please make sure you have
- Your DEA Number
- Your State Medical License Number
- Your Training Certificate Information

Do you work for the US military, Veterans Administration, or Indian Health Service?
- Yes
- No

Answer the question yes or no and click the Next button.
Check your eligibility

• Use the drop down menu to select your licensing state.
• Enter your medical license number, letter and numbers only. No spaces or dashes.
• Enter your DEA number, letter and numbers only.
• Click the Submit button.
*The system will indicate the number of patients you are eligible to submit a Notification for. Click the Next button.

*The state, medical license and DEA number will be pre-populated.
Complete Notification Form

1A. Enter your name and suffix. (M.D. or D.O.)
1B. Medical license number will be pre-populated
1C. License state will be pre-populated
1D. DEA number will be pre-populated
2. **Address** – if you are planning to store buprenorphine on site, you will need to provide the address you are listed under with DEA. Otherwise, you may provide an address in your licensing state. Do not enter a P.O. Box as your street address.

3. **Enter phone number**

4. **Enter fax number**

5. **Enter email address**, twice. Please provide an email address the regularly access. All correspondence from SAMHSA will be via email.
6. Purpose of Notification
the New box will be pre-checked
7. Check box, that you will only use approved Schedule III, IV, & V medications
8. Certification of Qualifying Criteria
Check the appropriate box if you have a sub-specialty in Addiction medicine or psychiatry.
Check the appropriate box for the 8 hour training course you completed.
Enter the date the training was completed.
Enter the city where the training was completed. If you have complete an on-line course type “web” for your city.
The state will be pre-populated but you may change it if it does not correspond with where you complete on site training.
9. **Certification of Capacity** Check box – must certify that you will refer patients for counseling.

10. **Certification of Maximum Patient Load** – button is pre-populated

11. **Consent to Release Contact Information** – click the “consent” or “do not consent” button

12. Check the box which states that you have not knowingly given false information.

---

**9. CERTIFICATION OF CAPACITY**

- I certify that I have the capacity to refer patients for appropriate counseling and other appropriate ancillary services.

**10. CERTIFICATION OF MAXIMUM PATIENT LOAD**

- I certify that I will not exceed 30 patients for maintenance or detoxification treatment at one time.
- Second Notification - I need to treat up to 100 patients and I certify that I will not exceed 100 patients for maintenance or detoxification treatment at one time.

The SAMHSA Buprenorphine Physician and Treatment Program Locator Web site is publicly accessible at [http://buprenorphine.samhsa.gov/bwns_locator](http://buprenorphine.samhsa.gov/bwns_locator). The Locator Web site lists the names and practice contact information of physicians with DATA waivers who agree to be listed on the site. The Locator Web site is used by the treatment-seeking public and health care professionals to find physicians with DATA waivers. The Locator Web site additionally provides links to many other sources of information on substance abuse. No physician listings on the SAMHSA Buprenorphine Physician and Treatment Program Locator Web site will be made without the express consent of the physician.

**11. CONSENT TO RELEASE IDENTIFYING INFORMATION TO SAMHSA BUPRENOPHINE PHYSICIAN AND TREATMENT PROGRAM LOCATOR WEB SITE**

- I consent to the release of my name, primary address, and phone number to the SAMHSA Buprenorphine Physician and Treatment Program Locator Web site.
- I do not consent to the release of my name, primary address, and phone number to the SAMHSA Buprenorphine Physician and Treatment Program Locator Web site.

12. I certify that the information presented above is true and correct to the best of my knowledge. I certify that I will notify SAMHSA at the address below if any of the information contained on this form changes. Note: Any false, fictitious, or fraudulent statements or information presented above or misrepresentations relative thereto may violate Federal laws and could subject you to prosecution, and/or monetary penalties, and or denial, revocation, or suspension of DEA registration. (See 18 USC § 1001; 31 USC §§ 3801–3812; 21 USC § 824.)
Type your name in the box as your signature. Type in your DEA number matching the one you entered initially. Click the Submit button.

12.

I certify that the information presented above is true and correct to the best of my knowledge. I certify that I will notify SAMHSA at the address below if any of the information contained on this form changes. Note: Any false, fictitious, or fraudulent statements or information presented above or misrepresentations relative thereto may violate Federal laws and could subject you to prosecution, and/or monetary penalties, and or denial, revocation, or suspension of DEA registration. (See 18 USC § 1001; 31 USC §§ 3801–3812; 21 USC § 824.)

Please type your name to sign this electronic form. Submission Date: 08/11/2016

Please re-enter your DEA Registration Number to verify:

Submit

This form is intended to facilitate the implementation of the provisions of 21 USC § 823(g)(2). The Secretary of DHHS will use the information provided to determine whether practitioners meet the qualifications for waivers from the separate registration requirements under the Controlled Substances Act (21 USC § 823(g)(1)). The Drug Enforcement Administration will assign an identification number to qualifying practitioners and the number will be included in the practitioner’s registration under 21 USC § 823(f).

Privacy Act Information
Authority: Section 303 of the Controlled Substances Act of 1970 (21 USC § 823(g)(2)). Purpose: To obtain information required to determine whether a practitioner meets the requirements of 21 USC § 823(g)(2). Routine Uses: Disclosures of information from this system are made to the following categories of users for the purposes stated:

[Blank]

[Signature]
When the Notification is submitted successfully you will receive a confirmation. If it has not, an error message will indicate what needs to be correct.
Overview of Clinical Tools
For More Information and FREE training and educational resources on Medication Assisted Treatment (MAT) visit www.pcssnow.org.

PCSS is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with the: Addiction Technology Transfer Center (ATTC); American Academy of Family Physicians (AAFP); American Academy of Neurology (AAN); American Academy of Pain Medicine (AAPM); American Academy of Pediatrics (AAP); American College of Emergency Physicians (ACEP); American College of Physicians (ACP); American Dental Association (ADA); American Medical Association (AMA); American Osteopathic Academy of Addiction Medicine (AOAAM); American Psychiatric Association (APA); American Psychiatric Nurses Association (APNA); American Society of Addiction Medicine (ASAM); American Society for Pain Management Nursing (ASPMN); Association for Medical Education and Research in Substance Abuse (AMERSA); International Nurses Society on Addictions (IntNSA); National Association of Community Health Centers (NACHC); National Association of Drug Court Professionals (NADCP), and the Southeast Consortium for Substance Abuse Training (SECSAT).

PCSS-MAT’s mission is to provide free, evidence-based resources to train clinicians and the public about the effectiveness of medications used for treating opioid addiction, including buprenorphine, naltrexone and methadone, in order to more effectively address this public health crisis.
PCSS Mentoring Program

• PCSS Mentor Program is designed to offer general information to clinicians about evidence-based clinical practices in prescribing medications for opioid addiction

• PCSS Mentors are a national network of providers with expertise in addictions, pain, evidence-based treatment including medication-assisted treatment

• 3-tiered approach allows every mentor/mentee relationship to be unique and catered to the specific needs of the mentee

• No cost

For more information visit: pcssNOW.org/clinical-coaching
PCSS Discussion Forum

Have a clinical question?

Ask a Colleague

A simple and direct way to receive an answer related to medication-assisted treatment. Designed to provide a prompt response to simple practice-related questions.

Ask Now

http://pcss.invisionzone.com/register
**PCSS** is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with:

| American Academy of Family Physicians | American Psychiatric Association |
| American Academy of Neurology         | American Society of Addiction Medicine |
| Addiction Technology Transfer Center  | American Society of Pain Management Nursing |
| American Academy of Pain Medicine     | Association for Medical Education and Research in Substance Abuse |
| American Academy of Pediatrics        | International Nurses Society on Addictions |
| American College of Emergency Physicians | American Psychiatric Nurses Association |
| American College of Physicians        | National Association of Community Health Centers |
| American Dental Association           | National Association of Drug Court Professionals |
| American Medical Association          | Southeastern Consortium for Substance Abuse Training |
| American Osteopathic Academy of Addiction Medicine | |